secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcus Biosciences, Inc. (RCUS)
CIK:        0001724521
Form:       8-K
Filed at:   2022-05-09T23:59:59+00:00
Accession:  0000950170-22-008484
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcus Q1 net loss $68M; ARC-7 domvanalimab arms continue to differentiate
-------------------------------------------------------------------------

- Cash $1.34B, up from $681M due to $725M from Gilead in Jan 2022; funding into 2026.
- Q1 revenue $18M (up from $9.5M YoY); net loss improved to $68M from $72.6M YoY.
- Third IA of ARC-7: domvanalimab arms showed meaningful differentiation in ORR and DoR vs anti-PD1 alone; no unexpected safety.
- Phase 3 STAR-121 (domvanalimab+zim+chemo vs pembro+chemo) for 1L NSCLC PD-L1 all-comers planned Q4 2022.
- R&D expenses $61.2M (down from $66.4M) due to cost-sharing with Gilead; G&A increased to $24M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1724521/000095017022008484/0000950170-22-008484-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1724521/000095017022008484/rcus-20220509.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-008484

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer